Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
- 20 November 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (1), 55-63
- https://doi.org/10.1016/s1470-2045(12)70490-4
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future PerspectivesSeminars in Oncology, 2012
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trialEuropean Journal of Cancer, 2012
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalysesJournal of Hepatology, 2012
- Targeting the HGF/Met signaling pathway in cancer therapyEmerging Therapeutic Targets, 2012
- Targeting MET in cancer: rationale and progressNature Reviews Cancer, 2012
- The present and the future landscape of treatment of advanced hepatocellular carcinomaDigestive and Liver Disease, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Nonsurgical treatment of hepatocellular carcinomaLiver Transplantation, 2000